Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 14/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.38 |
| ▸ | PPARG | P37231 | 13/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009839 | 1.00 | AKR1C3 (0.41) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL10010671 | 0.91 | PPARG (0.35) | AKR1C3AKR1C2AKR1B1AKR1C4AKR1C1 | |
| SCHEMBL10011668 | 0.91 | PPARG (0.35) | AKR1C3AKR1C2AKR1B1AKR1C4AKR1C1 | |
| SCHEMBL10011672 | 0.91 | PPARG (0.35) | AKR1C3AKR1C2AKR1B1AKR1C4AKR1C1 | |
| SCHEMBL10010677 | 0.91 | PPARG (0.35) | AKR1C3AKR1C2AKR1B1AKR1C4AKR1C1 | |
| SCHEMBL10009327 | 0.89 | PPARG (0.36) | PPARDFFAR1PPARGPPARA | |
| SCHEMBL10009325 | 0.89 | PPARG (0.36) | PPARDFFAR1PPARGPPARA | |
| SCHEMBL10009366 | 0.89 | FFAR1 (0.39) | PPARDFFAR1PPARGPPARA | |
| SCHEMBL1708211 | 0.88 | FFAR1 (0.35) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL1708308 | 0.88 | AKR1C3 (0.41) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | AKR1C3 2792/4885AKR1C2 2268/4885AKR1B10 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.